Inhibikase Therapeutics (IKT) announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT:
- Inhibikase Therapeutics, Inc. (IKT) Q4 Earnings Cheat Sheet
- Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals
- Inhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO
- Inhibikase Therapeutics Appoints Mark Iwicki as New CEO
- Inhibikase Therapeutics appoints Mark Iwicki as CEO